Aldosterone dysregulation, associated with obesity and primary aldosteronism, plays a role in the mechanism of uncontrolled hypertension . Lorundrostat, a novel aldosterone synthase inhibitor, has emerged as a potential solution. A phase 3 clinical trial has evaluated its efficacy in lowering blood pressure (BP) in 1,083 adults (mean age: 61.6 years) with uncontrolled or treatment-resistant hypertension who were receiving two to five antihypertensive medications. The study showed that 50 mg of lorundrostat led to a 16.9 mm Hg reduction in automated office systolic BP at week six, compared to 7.9 mm Hg with placebo.
Adverse events, mostly mild or moderate, occurred in 49.9% of participants. Hyponatremia, hyperkalemia, and reduced kidney function were observed more frequently with lorundrostat, though treatment discontinuation remained low. These findings suggest that lorundrostat is well…
